Cargando…
Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype
Barth syndrome (BTHS) is an X-linked disorder characterised by cardiac and skeletal myopathy, growth delay, neutropenia and 3-methylglutaconic aciduria (3-MGCA). Patients have TAZ gene mutations which affect metabolism of cardiolipin, resulting in low tetralinoleoyl cardiolipin (CL(4)), an increase...
Autores principales: | Bowron, Ann, Honeychurch, Julie, Williams, Maggie, Tsai-Goodman, Beverley, Clayton, Nicol, Jones, Lucy, Shortland, Graham J., Qureshi, Shakeel A., Heales, Simon J. R., Steward, Colin G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341014/ https://www.ncbi.nlm.nih.gov/pubmed/25112388 http://dx.doi.org/10.1007/s10545-014-9747-y |
Ejemplares similares
-
Erratum to: Barth syndrome without tetralinoleoyl cardiolipin deficiency: a possible ameliorated phenotype
por: Bowron, Ann, et al.
Publicado: (2015) -
Barth syndrome
por: Clarke, Sarah LN, et al.
Publicado: (2013) -
Treatment of Barth Syndrome by Cardiolipin Manipulation (CARDIOMAN) With Bezafibrate: Protocol for a Randomized Placebo-Controlled Pilot Trial Conducted in the Nationally Commissioned Barth Syndrome Service
por: Dabner, Lucy, et al.
Publicado: (2021) -
Loss of protein association causes cardiolipin degradation in Barth syndrome
por: Xu, Yang, et al.
Publicado: (2016) -
Evaluation of cardiolipin nanodisks as lipid replacement therapy for Barth syndrome
por: Ikon, Nikita, et al.
Publicado: (2018)